To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.
The proposed biospecimen repository would be derived from patients diagnosed with ILD. This is to include 500 patients in the repository, with each patient contributing one blood sample. Patients with pneumonia and healthy patients will also be recruited as a control group.
Study Type
OBSERVATIONAL
Enrollment
635
100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis
100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.
100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
Mayo Clinic
Rochester, Minnesota, United States
RECRUITINGFuture Disease Management
Reliable biomarkers to help guide treatment in ILD would be a major step forward in the management of this disease.
Time frame: 1 visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.